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Abstract
Introduction:  Chemotherapy  and  radiotherapy  in  oncology  have  repercussions  in  hearing  health,
and can  damage  structures  of  the  inner  ear.  These  repercussions  usually,  result  in  a  bilateral
and irreversible  hearing  loss.
Objective:  To  identify  sensorineural  hearing  loss  cases  with  complaints  of  tinnitus  and  difﬁculty
in speech  understanding  and  investigate  their  relationship  with  the  types  of  chemotherapy  and
radiotherapy  the  patients  received.
Methods:  Cross-sectional,  clinical,  observational,  analytical,  historical  cohort  study  of  58  sub-
jects treated  in  a  public  hospital  in  the  state  of  Sergipe,  diagnosed  with  neoplasia.  The  subjects
were submitted  to  anamnesis,  conventional  pure  tone  audiometry,  and  speech  recognition
threshold.
Results: Of  the  116  ears,  25.9%  presented  sensorioneural  hearing  loss  characterized  by  changes
in high  frequencies.  There  was  a  positive  correlation  between  hearing  loss  and  the  association
of chemotherapy  and  radiotherapy  (p  =  0.035;  R  =  0.196).  The  auditory  complaint  analysis  shows
that most  of  the  subjects  had  tinnitus  and  speech  understanding  difﬁculty,  even  with  a  normal
auditory threshold.
Conclusions:  Cancer  treatment  causes  hearing  loss,  associated  with  the  administration  of
chemotherapy  and  radiotherapy.  Cyclophosphamide  increased  the  risk  of  causing  hearing  loss.
Complaints  of  tinnitus  and  speech  understanding  difﬁculty  were  observed.
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Tratamento  oncológico  na  determinac¸ão das  alterac¸ões  auditivas
Resumo
Introduc¸ão:  O  tratamento  quimioterápico  e  radioterápico  na  oncologia  tem  repercussão  na
saúde auditiva  e  pode  lesar  estruturas  da  orelha  interna.  Ocasiona  perda  auditiva,  geralmente
bilateral e  irreversível.
Objetivo:  Identiﬁcar  casos  de  perda  auditiva  sensorioneural  e  sua  relac¸ão  com  a  média  de
sessões de  quimioterapia  e  radioterapia,  com  queixas  de  zumbido  e  diﬁculdade  de  entendimento
da fala,  bem  como  sua  relac¸ão  com  medicamentos  quimioterápicos.
Método:  Estudo  de  coorte  histórica  com  corte  transversal,  clínico,  observacional,  analítico  e
retrospectivo  em  58  sujeitos  de  um  hospital  público  de  Sergipe  diagnosticados  com  neopla-
sia. Realizou-se  anamnese,  avaliac¸ão  audiológica  tonal  convencional  e  pesquisa  do  limiar  de
reconhecimento  de  fala.
Resultados:  Das  116  orelhas;  25,9%  apresentaram  perda  auditiva  sensorioneural  caracterizada
por alterac¸ões  nas  frequências  agudas.  Observou-se  correlac¸ão  signiﬁcativa  entre  perda  audi-
tiva e  associac¸ão  da  quimioterapia  e  radioterapia  (p  =  0,035;  R  =  0,196).  Na  análise  das  queixas
auditivas,  veriﬁcou-se  que  a  maioria  apresentou  zumbido  e  diﬁculdade  de  entendimento  de
fala, mesmo  com  limiares  auditivos  normais.
Conclusões:  O  tratamento  oncológico  gera  perda  auditiva,  que  foi  determinada  pela  associac¸ão
da quimioterapia  e  radioterapia.  Ciclofosfamida  aumentou  as  chances  de  gerar  perda  auditiva.
Veriﬁcou-se  presenc¸a  de  queixas  de  zumbido  e  diﬁculdade  de  entendimento  da  fala.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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urrently,  cancer  is  considered  a  public  health  problem  with
igh  prevalence.  There  is  a  projection  of  27  million  new
ases  for  the  year  2030  worldwide  and  17  million  deaths
rom  the  disease.  In  Brazil,  estimates  for  the  year  2014/2015
eport  approximately  580,000  new  cases  of  the  disease.
mong  the  most  prevalent  forms,  non-melanoma  skin  can-
er,  prostate,  breast,  colorectal,  lung,  and  stomach  cancers
revail.1
The  basic  modalities  in  cancer  treatment  involve  surgery,
hemotherapy,  and  radiotherapy.  Currently,  the  combi-
ation  of  chemotherapy  and  radiotherapy  has  improved
atient  survival.  However,  none  of  these  treatment  modali-
ies  is  free  of  side  effects.  Among  their  effects,  hearing  loss
aused  by  ototoxicity,  can  be  documented.2--4
In  recent  years,  the  number  of  studies  reporting  the  inﬂu-
nce  of  chemotherapeutic  agents  on  hearing  function  has
ncreased.  The  drugs  employed  belong  to  different  classes,
nd  some  of  them  --  aminoglycosides,  antineoplastic  agents,
ntibiotics,  nonsteroidal  anti-inﬂammatory  drugs,  diuretics
nd  antihypertensives  --  are  considered  to  be  ototoxic  drugs.
rugs  included  in  the  platinum  group  are  the  most  devas-
ating,  generating  auditory  symptoms  such  as  tinnitus  and
earing  sensitivity  change.2,4,5 It  has  also  been  observed  that
incristine,  doxorubicin,  gemcitabine,  cyclophosphamide,
xaliplatin,  and  farmorubicin6 also  are  ototoxic.
Radiotherapy  can  also  damage  the  auditory  organ.  This
herapeutic  modality  promotes  tumor  cell  destruction  by  its
onizing  radiation  beams.  A  pre-calculated  dose  of  radiation
s  applied  to  tumor  cells  during  a  speciﬁed  time  period,  in  a
olume  of  tissue  that  includes  the  tumor.  Hearing  loss  is  most
t
a
sommonly  found  in  the  treatment  of  head  and  neck  tumors.
lthough  there  are  few  studies  focused  on  the  side  effects  of
adiotherapy  on  hearing  health,  the  literature  shows  a  wide
ariation  in  the  incidence  of  ototoxicity.3,7
In  both  treatments,  the  higher  concentration  of  toxic
ubstances  in  the  body  is  able  to  reach  the  organ  of  Corti
nd  sensory  epithelia  of  the  posterior  labyrinth,  through  the
abyrinthine  ﬂuids.  These  substances  compromise  mainly  the
uter  hair  cells  and  can  lead  to  cochlear  symptoms;  however,
estibular  disorders  may  arise  in  a  slow  or  insidious  way,  even
fter  the  end  of  treatment.  Usually,  hearing  loss  is  bilateral,
rreversible,  associated  with  tinnitus  and  is  high-frequency
n  audiometric  conﬁguration.3,5,8
Studies  investigating  hearing  in  oncologic  patients
sing  conventional  audiometric  frequencies,  report  variable
ymptoms.  It  is  common  to  observe  tinnitus,  difﬁculty  under-
tanding  conversation  in  noisy  environments,  and  changes  in
peech  discrimination.9
Studies  in  this  area  also  report  that  the  hearing  loss
aused  by  ototoxic  substances  is  often  underestimated.  Even
n  the  presence  of  a  hearing  disorder,  patients  only  report
earing  complaints  in  speciﬁc  situations,  such  as  in  noisy
nvironments.  Other  patients  only  exhibit  partial  under-
tanding  of  a  message,  which  makes  it  more  difﬁcult  for
elatives  to  detect  the  hearing  loss.10
Studies  on  oncology  and  hearing  health  sought  to  promote
arly  detection  of  hearing  impairment  and  to  implement
reventive  measures  in  order  to  improve  the  quality  of  life
f  this  population.  This  research  was  speciﬁc;  its  objec-
ives  were  to  identify  cases  of  sensorineural  hearing  loss
nd  their  relationship  with  chemotherapy  and  radiotherapy
ession  means,  and  with  tinnitus  and  speech  understanding
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Table  1  Distribution  of  pure  tone  threshold  means,  by
audiometric  frequency  test,  in  the  population  with  normal
audiograms  and  with  sensorineural  hearing  loss  (n  =  116).
Normal  hearing
thresholds  (dBNA)
Sensorineural  hearing
loss  (dBNA)
250  Hz  12.33  21.00
500 Hz  11.98  20.80
1000 Hz  10.52  25.40
2000 Hz  9.88  25.60
3000 Hz 10.35  25.40
4000 Hz 10.87 35.20
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difﬁculty  complaints,  as  well  as  their  relation  to  the  use  of
various  chemotherapy  drugs.
Methods
This  was  a  cross-sectional,  clinical,  observational,  analyt-
ical,  historical  cohort  study.  All  ethical  guidelines  were
followed,  and  this  project  was  approved  by  the  Research
Ethics  Committee,  under  protocol  No.  0066.0.107.000-11.
Data  collection  was  conducted  from  March  to  November
of  2013  in  the  physical  space  of  the  cancer  ward  of  a  public
hospital  in  Sergipe.  The  sample  comprised  58  subjects  aged
25--59  years  with  pathological  diagnosis  of  cancer  who  were
undergoing  chemotherapy  and/or  radiotherapy.  The  fol-
lowing  drugs  were  utilized  for  chemotherapy:  carboplatin,
cisplatin,  doxorubicin,  epirubicin,  farmorubicin,  vincristine,
actinomycin,  gemcitabine,  oxaliplatin,  cyclophosphamide
and  ﬂuorouracil.
Subjects  were  excluded  from  the  study  if  they:  were
over  60  years  of  age  (to  avoid  hearing  loss  by  age);  had  a
history  of  previous  ear  surgery;  worked  in  a  setting  with
noise  exposure;  had  previous  acoustic  trauma;  had  received
ototoxic  medication  prior  to  current  treatment;  had  infec-
tions  or  congenital  syndromes;  exhibited  outer  ear  canal
obstruction  and/or  had  previously  received  chemotherapy
and/or  radiotherapy.  In  addition,  subjects  with  a  diagnosis
of  head  and  neck  cancer  or  conductive  hearing  loss  were  also
excluded.
After  signing  the  informed  consent,  the  patients’  his-
tory  was  obtained  and  meatoscopy  and  conventional  pure
tone  audiometry  were  performed,  with  a  survey  for  speech
reception  threshold.
The  anamnesis  scheme  was  developed  by  the
researchers,  and  consisted  of  information  concerning
the  past  history  of  the  disease,  treatment  performed,  drugs
used,  time  of  use  of  the  drug,  initiation  of  therapy,  and
overall  hearing  health.
The  equipment  used  to  perform  pure  tone  audiometry
and  a  speech  reception  threshold  survey  was  the  Interacous-
tics  Ad  Model  229  B  audiometer  with  a  TDH-39  headset  in
a  soundproof  booth  that  followed  the  equipment  calibra-
tion  standards  proposed  by  the  Brazilian  Federal  Council  of
Phonoaudiology  on  environmental  noise  measurement  (res-
olution  No.  365  of  March  30,  2009).  On  examination  of  pure
tone  audiometry,  hearing  thresholds  were  surveyed  by  inte-
roctave  frequencies  of  0.25--8  kHz  by  air  conduction  and
of  0.5--4  kHz  by  bone  conduction.  The  speech  recognition
threshold  survey  was  conducted  to  conﬁrm  the  tonal  ﬁnd-
ings.
Thus,  using  the  tonal  audiometry  ﬁndings,  the  sample  was
organized  into  two  groups:  Group  1,  consisting  of  ears  with
normal  hearing  thresholds,  and  Group  2,  ears  with  hearing
loss.
Data  were  tabulated  and  processed  by  the  software  Sta-
tistical  Package  for  Social  Sciences  (SPSS),  version  17.0.  For
a  description  of  data,  tabular  presentation  of  means,  medi-
ans,  standard  deviations,  maximum  and  minimum  values,
and  percentages  were  used.  Sample  normality  was  veriﬁed
using  the  Shapiro--Wilk  test.  To  evaluate  the  relationship
between  variables,  the  Mann--Whitney  and  bivariate  correla-
tion  (Spearman  coefﬁcient)  tests  were  utilized.  Values  were
w
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p6000  Hz 13.66 39.80
8000  Hz 12.62 43.00
onsidered  signiﬁcant  at  p  ≤  0.05  and  the  admitted  ˛  value
as  0.1.
esults
he  sample  consisted  of  58  subjects  (116  ears)  with  female
redominance  (93.1%),  and  mean  age  of  47.19  (±9.36)
ears.  For  Group  1,  the  mean  age  was  46.56  (±9.38),  and
or  Group  2,  51.93  (±9.38)  years.
The  most  frequent  diagnosis  was  breast  cancer  (69%),  fol-
owed  by  cervical  (8.6%)  and  uterine  (5.2%)  cancers.  Among
he  therapeutic  procedures  recommended  by  the  medi-
al  staff,  it  was  noted  that  84.5%  underwent  surgery,  and
atients  were  also  referred  for  chemotherapy  and/or  radio-
herapy.  Chemotherapy  and  radiotherapy  usually  occurred
fter  surgery;  37.9%  underwent  chemotherapy,  15.5%  radio-
herapy,  and  46.6%  both  chemotherapy  and  radiotherapy.
The  number  of  chemotherapy  sessions  ranged  from  one
o  36,  with  a  mean  of  7.56  sessions;  while  the  number  of
adiotherapy  sessions  ranged  from  one  to  70,  with  a  mean
f  18.31.  By  the  time  audiological  evaluations  were  carried
ut,  1.7%  of  the  population  were  starting  treatment;  53.4%
ere  in  progress,  and  44.8%  had  completed  treatment.
The  studied  population  used  either  a  single  chemothera-
eutic  agent  or  a  combination  of  several  drugs.  The  patients
sed  the  following  drugs:  carboplatin  (n  =  2),  cisplatin
n  =  6),  doxorubicin  (n  = 6),  epirubicin  (n  =  9),  farmorubicin
n  =  1),  vincristine  (n  =  1)  actinomycin  (n  =  1),  gemcitabine
n  =  6),  and  oxaliplatin  (n  =  3);  the  most  frequently  used
gents  were  ﬂuorouracil  (n  =  17)  and  cyclophosphamide
n  =  18).
Of  the  116  ears  submitted  for  audiological  evaluation,  30
25.9%)  exhibited  sensorineural  hearing  loss,  predominantly
n  the  high  frequencies.  Audiometric  analysis  of  the  hearing
oss  cases  revealed  that  worsening  of  tonal  auditory  thresh-
lds  began  at  the  frequency  of  4  kHz  and  gradually  increased
t  the  higher  frequencies  of  6  and  8  kHz  (Table  1).
In  cancer  treatment,  a  positive  bivariate  correlation
as  found  between  hearing  loss  and  the  combination  of
hemotherapy  and  radiotherapy,  with  p-value  =  0.035  and
orrelation  coefﬁcient  R  =  0.196.  No  signiﬁcant  relationship
as  observed  for  these  treatments  in  isolation,  as  may  be
een  in  Table  2, and  the  number  of  chemotherapy  and  radio-
herapy  sessions  was  not  signiﬁcant  for  determining  the
resence  of  hearing  loss.
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Table  2  Distribution  of  oncology  treatment  sessions  in  the
studied  population  (n  =  58).
Group  1  Group  2  Mann--Whitney
testa
Chemotherapy
sessions,
mean
7.93  6.44  p  =  0.113
Radiotherapy
sessions,
mean
18.26  18.46  p  =  0.616
a Signiﬁcant p-value ≤ 0.05.
Table  3  p-Value  calculated  for  the  correlation  between
drug used  in  chemotherapy  vs.  presence  of  hearing  loss
(n =  30).
Drugs  p-Valuea R-value
Cyclophosphamide  0.034b 0.211
Carboplatin  0.66 --
Cisplatin  0.57 --
Doxorubicin  0.57 --
Epirubicin  0.89  --
Fluorouracil  1.00  --
Vincristine  0.39  --
Actinomycin  0.39  --
Gemcitabine  0.57  --
Oxaliplatin  0.18  --
p
s
G
3
p
p
i
c
l
a
D
I
l
l
s
G
w
w
a
l
t
e
b
c
t
b
k
t
c
w
t
l
i
w
s
f
o
m
d
i
a
f
N
t
a
2
t
s
w
p
w
b
o
c
6
i
u
i
i
e
a
w
t
g
g
t
d
b
dR, correlation coefﬁcient.
a Bivariate correlation test (Spearman’s coefﬁcient).
b Signiﬁcant p-value ≤ 0.05.
Regarding  the  type  of  chemotherapy  drug  used  in  the
opulation  presenting  hearing  loss,  only  cyclophosphamide
howed  a  signiﬁcant  correlation  (Table  3).
With  respect  to  self-reported  hearing  complaints  by
roup  1,  62.8%  reported  having  a  perception  of  tinnitus  and
2.6%  had  difﬁculty  listening;  while  in  Group  2,  60.0%  com-
lained  of  tinnitus  and  40.0%  had  difﬁculty  listening.  The
resence  of  tinnitus  was  often  observed,  even  without  hear-
ng  loss  (p  =  0.79),  and  also  occurred  in  conjunction  with
omplaints  of  difﬁculty  in  understanding  speech  (p  =  0.46).
Of  the  15  subjects  (30  ears)  who  experienced  hearing
oss,  23.3%  reported  worsening  of  hearing  after  chemother-
py  and  6.7%  after  radiotherapy.
iscussion
n  this  study,  most  participants  were  female,  with  preva-
ence  of  breast  cancer,  which  conﬁrm  the  ﬁndings  in  the
iterature  for  the  state  of  Sergipe  in  2014/2015.1
The  population  studied  had  a  mean  age  over  40  years,
imilar  to  that  found  in  previous  studies.11 The  subjects  in
roup  2  were  older,  compared  to  Group  1,  and  such  data
ere  also  reported  in  the  literature.12
Most  respondents  (84.5%)  underwent  surgery,  and  then
ere  treated  with  chemotherapy  and/or  radiotherapy.  The
dopted  medical  management  was  also  described  in  the
iterature,  considering  that,  in  the  early  staging  process,
he  recommended  treatment  is  surgery.  This  procedure
C
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nables  a  complete  removal  of  the  tumor  and  provides  a
etter  chance  of  survival.  Subsequently,  radiotherapy  and
hemotherapy  are  performed,  independently  or  together.13
Most  often,  the  medical  team  opted  for  a  combina-
ion  of  chemotherapy  and  radiotherapy  (46.6%),  followed
y  chemotherapy  (37.9%)  and  radiotherapy  (15.5%).  It  is
nown  that  the  type  of  treatment  recommended  is  related
o  the  type  of  tumor;  and  in  the  literature,  high  values  for
hemotherapy  were  found.13
With  respect  to  the  use  of  chemotherapeutic  agents,  it
as  found  that  cyclophosphamide  was  more  signiﬁcant  in
he  determination  of  changes  in  auditory  threshold;  in  the
iterature,  this  agent  is  referred  to  as  ototoxic,  possibly
njuring  cochlear  hair  cells.14
Hearing  loss  was  mainly  sensorineural,  which  is  consistent
ith  hearing  loss  caused  by  cochlear  ototoxic
ubstances,  with  early  involvement  of  high
requencies.2,3,11,15,16
In  the  audiometric  analysis,  hearing  threshold  worsening
ccurred  at  and  above  the  frequency  of  4  kHz.  Among  the
ost  affected  frequencies,  changes  in  6--8  kHz  have  been
iagnosed,  which  is  in  line  with  the  literature.17 Researchers
n  the  area  report  that  the  ﬁrst  frequencies  to  be  affected
re  high  (6  kHz  and  8  kHz);  and  that  during  the  patient’s
ollow-up,  hearing  loss  can  advance  to  low  frequencies.
onetheless,  other  studies  have  been  published  reporting
hat  the  higher  prevalence  occurs  at  the  frequencies  of  3  kHz
nd  4  kHz.11
It  was  found  that,  of  the  15  subjects  with  hearing  loss,
3.3%  reported  worsening  of  post-chemotherapy  hearing
hresholds,  and  6.7%  reported  after  radiotherapy,  with  con-
equent  hearing  complaints.  Studies  have  indicated  that
hen  there  is  change  at  the  4  kHz  frequency,  hearing  com-
laints  may  occur.  Thus,  these  data  explain  the  hearing
orsening  in  the  population  studied,  since  it  was  possi-
le  to  detect  hearing  change  from  the  frequency  of  4  kHz
nwards.10
The  presence  of  tinnitus  was  considered  as  a  relevant
omplaint.  Tinnitus  occurred  in  62.8%  of  Group  1  and  in
0.0%  of  Group  2.  The  literature  also  indicates  a  high
ncidence  of  tinnitus  --  a common  occurrence  in  patients
ndergoing  cancer  treatment,  which  can  be  observed  even
n  the  absence  of  hearing  loss.2,15,17,18
There  was  no  correlation  between  ‘‘difﬁculty  in  listen-
ng’’  and  ‘‘suffering  hearing  loss.’’  This  ﬁnding  can  be
xplained  by  the  fact  that  the  most  affected  frequencies
re  the  highest  ones,  and  the  complaints  are  more  frequent
hen  they  reach  the  speech  range.17
With  respect  to  cancer  treatment,  the  means  of  radio-
herapy  and  chemotherapy  sessions  were  similar  for  both
roups.  The  literature  reports  they  need  to  consider  that  the
reater  the  time  of  presence  of  toxic  substances  in  the  body,
he  greater  the  adverse  effect,  although  there  are  individual
ifferences  in  response  to  toxic  agents,  as  well  as  varia-
les  that  enable  ototoxicity,  e.g.,  family  antecedents  with
eafness  and  individual  susceptibility,  among  others.17,19onclusion
earing  loss  in  subjects  undergoing  cancer  treatment
as  observed,  and  the  combination  of  chemotherapy
11
1
1
1
1
1
1
1
19. Almeida EOC, Costa CB, Oliveira SRT, Umeoka MTH. Audiome-Cancer  treatment  in  determination  of  hearing  loss  
and  radiotherapy  was  instrumental  for  the  change  in
hearing  thresholds.  Cyclophosphamide  was  the  most  fre-
quently  administered  chemotherapeutic  agent  and  was
positively  correlated  with  hearing  loss.  In  the  population
submitted  to  cancer  treatment,  a  high  prevalence  of  tinni-
tus  and  speech  understanding  difﬁculty  were  found,  even  in
the  absence  of  hearing  loss.
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